Interplay of protein corona and immune cells controls blood residency of liposomes
Open Access
- 15 August 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-11
Abstract
In vivo liposomes, like other types of nanoparticles, acquire a totally new ‘biological identity’ due to the formation of a biomolecular coating known as the protein corona that depends on and modifies the liposomes’ synthetic identity. The liposome–protein corona is a dynamic interface that regulates the interaction of liposomes with the physiological environment. Here we show that the biological identity of liposomes is clearly linked to their sequestration from peripheral blood mononuclear cells (PBMCs) of healthy donors that ultimately leads to removal from the bloodstream. Pre-coating liposomes with an artificial corona made of human plasma proteins drastically reduces capture by circulating leukocytes in whole blood and may be an effective strategy to enable prolonged circulation in vivo. We conclude with a critical assessment of the key concepts of liposome technology that need to be reviewed for its definitive clinical translation.Keywords
This publication has 63 references indexed in Scilit:
- Temperature: The “Ignored” Factor at the NanoBio InterfaceACS Nano, 2013
- Understanding and controlling the interaction of nanomaterials with proteins in a physiological environmentChemical Society Reviews, 2011
- Physical−Chemical Aspects of Protein Corona: Relevance toin Vitroandin VivoBiological Impacts of NanoparticlesJournal of the American Chemical Society, 2011
- Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammationNature Nanotechnology, 2010
- Liposome triggering of innate immune responses: A perspective on benefits and adverse reactionsJournal of Liposome Research, 2009
- Nanoparticle size and surface properties determine the protein corona with possible implications for biological impactsProceedings of the National Academy of Sciences, 2008
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Size Dependent Liposome Degradation in Blood:In vivo/In vitroCorrelation by Kinetic ModelingJournal of Drug Targeting, 1995
- Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophagesBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1988
- Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol‐rich liposomesFEBS Letters, 1988